Mode
Text Size
Log in / Sign up
N/A N=925

Comparison of Outcomes of Complex Abdominal Aortic Aneurysm Treatment

Juxtarenal Aortic Aneurysm · Pararenal Aneurysm

Enrolled (actual)
925
Serious AEs
22.1%
Results posted
Jul 2024
Primary outcome: Primary: Aortic Related Reintervention. — 44; 63 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Open surgery and complex EVAR due to AAA (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Clinical Centre of Serbia
Primary completion
Jan 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Aortic Related Reintervention.
44; 63
PRIMARY
All-cause Mortality
256; 91
SECONDARY
30-day Acute Kidney Injury
182; 39

Summary

Background: Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components, and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate, and low morbidity and mortality, with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR). Aim: The aim of this study will be to compare F/BEVAR versus open AAA repair on short- and long-term clinical outcomes for the treatment of juxta- and pararenal AAA. Methodology: This is a prospective cohort study from the four high-volume AAA repair centers: Belgrade/Serbia, Bologna/Italy, Milan/Italy, Dijklander/Netherland, Amsterdam/Netherland, and Helsinki/Finland. Data will be collected on demographics, baseline comorbidities, AAA parameters (diameter and localization), laboratory values, intra-, and postoperative data. Follow-up examinations (clinical visits and color duplex ultrasonography, CT scans) will be performed 1, 6, and 12 months after the intervention, and annually thereafter. Propensity score analysis will be performed by matching open repair patients to endovascularly treated controlling for demographics and baseline comorbidities. Endpoints: Primary endpoints are all-cause mortality and the freedom from aortic-related reintervention. The secondary endpoint is the 30-day complication rate, especially acute kidney injury according to the RIFLE criteria.

Eligibility Criteria

Inclusion Criteria

  • All patients (over 18 years of age) with a history of juxta- and pararenal AAA repair from January 2011 to January 2022
  • All management strategies will be included (endovascular and open)

Exclusion Criteria

  • Patients who are pregnant
  • Patients who are under 18 years of age
  • Patients who have ruptured AAA
  • Patients with thoracoabdominal aortic aneurysm (ThAAA)
  • Patients who have a mycotic AAA
  • Patients with connective tissue disorder
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04773223). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search